Jul
24

From North Dakota, proof that Blunt was railroaded

Last Friday the news couldn’t have been much worse for ex North Dakota state work comp fund CEO Sandy Blunt: the state’s Supreme Court affirmed his felony conviction on charges of theft. I spoke with Sandy that day, and can only report that he was all but devastated by the ruling.
What a difference a week makes. This morning, Sandy must have a whole different outlook – the prosecutor who convicted him is herself under investigation for allegedly suborning perjury and prosecutorial misconduct.
Late this week sources informed me that the state’s bar association was about to begin a formal ‘trial’ of Cynthia Feland based on evidence she withheld information from Blunt and his defense attorney. While this isn’t an actual criminal proceeding, it is quite serious, as the allegations, if upheld, are grave enough to result in Feland’s disbarment for life.
As I reported months ago, “I contacted Feland several times over the last few weeks, asked her directly about this situation, and she refused to address the key question – had she provided Blunt with a copy of the State Auditor’s memo which cleared Blunt of any malfeasance related to Spencer?…” You can read her response to my query, but here’s the net – The prosecutor has no record of providing the defense with a document that would have allowed the defense to prove that the prosecution’s main charge was not a crime.
While I couldn’t force the issue, the state Bar Association, and the county sheriff, have.
The details are beginning to come out. This morning’s Bismarck Tribune had a front-page, above-the-fold article detailing the allegations against Feland. Although Feland pooh-poohed the proceedings, according to the Tribune, “Sending a case to the Disciplinary Board for formal proceedings means “basically, they’re making a finding that there’s probable cause that misconduct occurred,” [ND Supreme Court Clerk Penny] Miller said.”
As assistant prosecutor, Feland personally led the state’s prosecution of Blunt.
The evidence was brought to the attention of the ND Bar Association by Steve Cates, author of the North Dakota Beacon and one of Sandy’s long time supporters. Case has diligently and persistently pursued the facts in this case for more than a year and a half, poring over thousands of pages of transcripts, reviewing each and every exhibit and scrap of evidence.
In the course of Cates’ research it became apparent that Feland had failed to turn over exculpatory evidence, evidence that would have proven Blunt’s contention that a state auditor had reported that most of the charges against him should never have been brought.
Not only did Feland withhold evidence, but she knew, before she brought the charges, that several of the charges weren’t crimes. And even more seriously, Feland suborned perjury by getting a key prosecution witness, Jason Wahl, to lie on the stand.
Feland isn’t the only prosecutor in hot water over their mishandling of the case. According to the Tribune, “The documents obtained by the Tribune said the Inquiry Committee West also found that Riha [Feland’s boss] was issued an admonition for violating rules 5.1(a) and (b) of the Rules of Professional Conduct by not making sure that the attorneys in his office were conforming to the rules of professional conduct. The admonition also was issued against Riha for violating rule 3.8(d) of the Rules of Professional Conduct for his office not turning over a Nov. 8, 2007, memorandum from Jason M. Wahl in the state auditor’s office to Feland.“[emphasis added]
The Wahl memo indicated Blunt’s actions regarding a discharged fund employee, actions that Feland had said were illegal, were perfectly legal.
Sources also indicate, and I have confirmed, that the county sheriff has launched a criminal inquiry into Feland based on alleged perjury charges. The charges stem from Feland’s statement to the judge at Blunt’s trial that all charges against Sandy had been sent to Blunt’s defense counsel before trial. It now appears that Feland knew this wasn’t true.
At long last, the truth is beginning to come out. Blunt was convicted, and his conviction upheld, due to prosecutorial misconduct. Simply put, he was railroaded by a prosecutor who accused him of crimes he didn’t commit and lied to the judge during the trial.
Sandy can’t get his life, or his reputation back. Here’s hoping he makes the Burleigh County prosecutors pay for what they did to him, and make it abundantly clear that these criminal actions carry a very heavy penalty.


Jul
21

Work comp cost drivers – NCCI’s update and implications

The good folks at NCCI just released a report [opens pdf] detailing workers comp medical cost drivers; there are two ‘headline’ findings; severity is increasing at a slower rate, and the price of medical services is becoming a larger contributor to overall cost increases.
(The studies are based on lost time claims closed within 24 months of accident, so an increase in the length of time claims are open or the number of claims open longer than 24 months won’t show up.)
A quick side note than we’ll discuss these and other findings. The study covers experience through 2006, thus changes over the last three plus years are not considered. As I’ve reported here and NCCI has covered in many papers, several components of medical have seen rather significant changes since 2006: pharmacy costs are up; facility costs are spiking; surgical expenses, driven in large part by implants have increased dramatically in several ares; physical medicine costs in several jurisdictions are down and imaging expenses appear under control, due in large part to the impact of networks.
The big news is the increase in utilization has tapered off; we haven’t seen fewer medical services, but we also haven’t seen continued growth in the number of services provided to claimants. I’d hasten to add that while this is good news, we’re still dealing with too many services delivered to to many claimants.
The bleeding isn’t getting worse, but it’s still pretty bad.
The price issue is troubling. Most of the 21% increase in severity was due to higher prices for medical services, this at a time when the utilization of provider networks, offering discounted pricing for medical services, has grown significantly. PPO penetration, on a national average basis, is in the 60% range with wide variation among states – NJ and FL commonly see rates above 85%, while Texas and California are closer to 50%.

PPO penetration has increased significantly over time, yet prices have also grown. There are several potential explanations for this:

a) a change in utilization patterns over time, wherein more expensive procedures are used more often. This doesn’t appear to be the case, as the NCCI study accounted for changes in service type.
b) an increase in fee schedules. again, this doesn’t appear likely as most fee schedules have seen modest increases, with a couple notable exceptions.
c) increased provider pricing in UCR states. I’m thinking this has undoubtedly contributed to price increases. UCR pricing (usual, customary, and reasonable) are based on charges (not payments) for that procedure in that area in the preceding time period. Historically, UCR increases by double digits each year.
d) increased provider leverage in contracting. There’s no doubt this has contributed to cost increases, as we’ve seen in California, Illinois, and many other states.
What does this mean for you?
You will want to assess how the prices you’ve been paying for specific procedures (and the number of procedures themselves) have changed over the past few years to see if NCCI’s findings re price and utilization have continued since 2006.


Jul
16

Should Medicaid be the basis for work comp drug fee schedules?

There’s a good bit of activity on the regulatory front as states with work comp pharmacy fee schedules consider possible changes to address the myriad issues inherent in AWP.
A little background will help frame the issue.
First, it’s important to understand the fee schedule amount is only paid if the script doesn’t go thru a PBM, and the vast majority of scripts do go thru a PBM, ensuring the carrier/employer/fund pays substantially less than the fee schedule.
My firm’s survey of large payers indicates network penetration was 82% in 2008. Therefore, fewer than one in five scripts are paid at fee schedule.
Some think setting a fee schedule at Medicaid solves the problem neatly. Were it only that simple.
Let’s look at California, which is the only state using Medicaid (known as Medi-Cal in CA). In point of fact, drug costs per claim are up 72% despite a fee schedule reduction that cut price more than 25%. Clearly, the lower fee schedule did NOT control cost.
I believe what has suffered is the clinical management of drugs; as evidenced by CWCI’s recent report narcotic opioid usage is up 600% over the last few years. In addition, cost per claim is up dramatically – driven primarily by utilization.
Medicaid could be used as the basis for a reimbursement calculation, however Medicaid has several inherent problems.
First, it is a political football, subject to the political winds
. This has caused significant problems in New York already, and has led regulators in California to prevent implementation of the lower MediCal reimbursement rates for work comp. As state budgets become increasingly constrained and as Medicaid greatly expands, we will undoubtedly see more states seek to reduce program costs by price reductions – simple, politically palatable, and score-able.
Second, Medicaid doesn’t cover a some drugs used in comp, especially pain meds and drugs that are not on individual states’ Medicaid formularies. As states seek cost reductions beyond those available from simple across-the-board fee cuts, they will move to tighter formularies covering far fewer medications, reference pricing, and other mechanisms that will effectively limit the drugs on the ‘fee schedule’.
As a result, a Medicaid-based fee schedule would be the subject of ongoing lobbying activity and legislative/regulatory action as it requires constant ‘maintenance’; legislators change reimbursement, drugs came on and off formulary, prices go up and down.
In terms of alternatives, WAC, AWP, and some of the other methodologies are inherently flawed. However there are other standards – standards such as Federal Supply Schedule, Average Manufacturers’ Price that are not subject to the same flawed processes as AWP. Examining these may help stakeholders assess their usefulness as an alternative.
(for a synopsis of the various pricing metrics, click here.
What does this mean for you?
1. Fee schedules for drugs are not applicable to most drugs paid under workers comp as PBM rates apply.
2.States will move away from AWP; it will be important to understand the alternatives, their pros and cons.


Jul
15

Narcotic usage in workers comp – what’s really going on?

There’s a bit of confusion in the comp pharmacy management space, as there appears to be contradictory evidence from two respected sources about the use of narcotic opioids in workers comp.
First, everyone agrees there’s just far too many claimaints getting far too many far too potent narcotics. Perhaps not in those exact terms, but close enough. Heavy duty, potent, potentially addictive, divertable, high-street-value drugs are dispensed far too often in comp.
But there is a bit of disagreement about exactly what’s going on.
First, CWCI, the always-authoritative California Workers Comp Institute, has been researching and reporting on this problem for several years, and their data shows the use of narcotic opioids is increasing. Dramatically.
In contrast, one of the largest work comp PBMs, PMSI, recently published their results which indicate a decline in usage of this type of drug early on in the claim cycle. I asked Maria Sciame, PharmD, PMSI’s Director of Clinical Services what she thought might account for the decrease in the use of opioid analgesics in the acute phase of injury.
Here’s her take (and I quote):
1. increased physician awareness of the potential negative effects of opioids
2. additional organized opioid monitoring strategies (mandatory reporting) associated with opioids may have reduced “off the cuff” opioid prescribing
3. increased awareness of pain management guidelines that call for non-opioids for the initial treatment of mild to moderate pain
4. decreased prescriber fear regarding the use of non-steroidal anti-inflammatory agents over the past year…remember the FDA warnings that have been issued within the past few years regarding the negative cardiovascular affects associated with NSAID use…started with Vioxx…physicians are becoming less cautious and have regained their comfort level with the use of NSAIDs again; thus, replacing narcotics for acute injuries with NSAIDS.
There are a couple other factors worth considering.
a) PMSI’s business all flows thru a PBM, whereas CWCI’s script data is from payers that use PBMs and some that don’t (even in this day and age, some payers don’t use PBMs; go figure). PBMs have clinical management programs in place to address things like early usage of narcotics.
b) CWCI’s data isn’t specific to early usage, whereas PMSI’s is (in this instance)
c) CWCI is specific to California; PMSI’s is national and as NCCI has reported, there are dramatic differences in prescribing patterns across states. NCCI’s research also indicates narcotic usage across the country has stabilized somewhat of late after several years of consistent increases.
So, what does this mean for you?
If you aren’t using a PBM, get with the program.
If you are, find out if they are actively, assertively, and effectively managing narcotic opioid scripts and claimants on those scripts. If they aren’t, find out why not (hint, it may be because you’re not able to provide data or support their efforts, if that’s not it, they’ve got some explaining to do)
Ask for data on narcotic usage for claims less than a year old, and older ones as well, and decide if your results are acceptable.


Jul
14

Work comp pharmacy – one company’s experience

The work comp pharmacy benefit management industry is growing increasingly sophisticated, and the release of PMSI’s Annual Drug Trends Report this morning adds to the trend.
Many of the larger work comp PBMs produce similar reports, providing deep insights into cost drivers, the effectiveness of solutions, and trends that anyone with any responsibility for med loss would be well advised to read.
Here are the quick takes from my admittedly not in-depth read of PMSI’s effort.
1. Price was up significantly last year, climbing 4.7%. This is heavily influenced by the price increases pushed thru by big pharma on brand drugs last year in anticipation of health reform.
2. Utilization was up only slightly, driven by more days supply per script.
3. Mail order utilization was up 3.6%, which undoubtedly contributed to the higher utilization as mail order scripts tend to include more days’ supply than those dispensed by retail stores.
4. The average number of scripts per injured worker was 11.1 in 2009. Yep, eleven point one. That’s a lot of drugs.
5. The report includes an interesting chart graphically illustrating the impact of the age of the claim on scripts per claimant; claims a year old typically had around three scripts at an average price per script of thirty bucks or so; in contrast ten year old claims had 23 scripts averaging over $180 each.

6. Generic efficiency (the percentage of scripts that could have been filled with a generic version) remained at 92%. This is driven by several factors, including state regulations (some have mandatory generic language and others are considering adopting it), PBM and payer intervention and outreach, and the ‘macro’ pharmacy market’s introduction of new brands. Generic efficiency and ‘conversion’ is key to cost management; according to PMSI (and consistent with other reports) each one point increase in generic utilization reduces cost by 1.4%.
7. Pharmacy in comp remains primarily, and I’d argue overwhelmingly, driven by pain. PMSI’s data suggests over three-quarters of drug spend was for pain management – one of the key differences between work comp pharmacy and group/Medicare pharmacy.
8. Our old nemesis OxyContin again accounted for a lot of comp dollars, with 9.9% of spend allocated to the brand and generic versions. On the good news side, Actiq and Fentora usage declined significantly (type ‘actiq’ into the ‘search this site’ text box above and to the right for plenty of reasons why this is a very good thing).
9. Finally, the average days supply of narcotic analgesicvs was up 6.4% while the number of claimants getting those drugs actually declined. This may be due to those claimants who could use alternative meds getting off narcotics (or not starting on them in the first place). As a result, the claimants still taking these drugs are more likely to need more meds.
There’s a lot more meat in the report, lots of detail on which drugs are driving how much utilization, changes in utilization by class of drug, and most importantly, the impact of clinical programs on utilization and drug mix.
What does this mean to you?
Two things.
While PMSI is one of the largest PBMs, remember that these data refer to their customers’ experience and therefore may not be exactly equivalent to your book of business. That said, don’t use that as an excuse if your stats aren’t up to snuff – instead look for ways to get better.
As you pack for that summer vacation, grab a copy of your PBM’s report (go to their site and find it there, or call your rep and have them send it over) and perhaps a couple others.
You know you want to, and you can always hide it inside a Cosmo or Men’s Health to prevent mocking stares from the knuckleheads on the next beach towel.


Jul
12

What’s ‘severity’?

In the work comp world there’s an oft-used term used to describe medical costs – ‘severity’.
I’m beginning to think that word itself is a problem, and perhaps is part of the reason the work comp payer community has proven itself, with few exceptions, unable to effectively manage medical expense.
There are any number of meanings for the term itself, but as it is used in the claim world ‘severity’ refers to the medical cost of a claim, or when used more broadly, medical costs overall (e.g. Severity of lost time claims increased in 2008 by xx%).
Severity is something that sort of just happens – a claim is either really severe or it isn’t. Severity is driven by uncontrollable factors and thus we can only deal with the fallout, or results, or impact of severity.
Severity happens.
It does, but only if we let severity ‘happen’. In reality, medical costs are much more controllable than many think; severity doesn’t have to happen to you, unless you passively allow it to. But because we’ve grown accustomed to hearing things like “claims costs increased driven by a 9% increase in medical severity”, we think ‘oh well, there’s that severity again, yawn…”
What we should be doing is asking a lot more ‘why’ and ‘how’ questions, and using the answers, or lack thereof, as the basis for actions to control severity:
– why is severity increasing?
– what specific areas and types of medical expenses are up?
– is there a region or state that appears to be up more than others?
– what are we not doing and why are our present programs not controlling cost?
– how do our results compare to our competitors? why? what are they doing differently?
Because the fact is, ‘severity’ is controllable – if you’re willing to ask the hard questions and address some perhaps uncomfortable answers; able to concede that your programs aren’t really ‘best in class’, and willing to adjust, retool, and revamp processes to drive better results.
In my experience most comp payers aren’t willing to do what it takes to control severity. And that’s why ‘severity’ controls them.


Jul
9

Illinois’ attempt to control surgical implant costs

Today’s WorkCompCentral edition [sub req] reported on an emergency revision to Illinois’ state workers comp fee schedule that will change the methodology for repricing surgical implant devices.
The move is a response to what the Illinois Workers Comp Commission described as ‘price gouging’. In the announcement, [opens pdf] the state noted “some providers have inflated their reported charges for implants so high that the final reimbursement is as much as 33% over the average cost from other providers.
The previous rate was set at 65% of billed charges; the new reg sets reimbursement at 25% over manufacturer’s net invoice price. The rationale for this? The “reimbursement rate is reasonable. It provides a significant profit margin while providing cost-containment and certainty for payers. In addition, in order to arrive at an accurate provider’s cost, the Commission decided that the invoice price would be net of any rebates but also that actual and customary shipping costs for the implants additionally would be reimbursed.”
What does this mean?
Well, using an invoice plus is better than a discount off billed charges, which has to be the most easily-gamed pricing methodology every conceived. Factoring in rebates is a good step as well; to my knowledge IL is the only state that considers the impact of rebates. And stating reimbursement is for the NET manufacturer’s invoice price will help forestall gaming the invoice as well.
The challenge lies in determining what ‘rebate’ means, how it will be determined, reported, and factored into pricing, and how ‘net’ will be defined.
As I noted in a post a while back, The problem lies in the documentation of the paid amount. Most payers ask for a copy of the invoice, which, on the surface, makes sense – this is what was paid.
Not exactly. What the invoice doesn’t show can include:
– volume purchase discounts
– rebates
– “3 for the price of 2” deals
– waste (some surgeons use the cage from one kit and screws from another, so the payer is paying for more hardward than is actually being used)
– internally developed invoices (documents prepared not by the supplier but by the provider)
This last point is the crux of the issue. Hospital systems often buy in bulk, with several implant kits shipped and billed; this obviously makes it impossible for the provider to produce the invoice for the device used in a specific surgery, as they never got one. Thus, many providers develop the invoice for a specific implant kit themselves.
There’s another problem with implants – when they are defective, the patient has to go back in for more surgery. And the WC insurer has to pay. The only way to mitigate risk is to track the model and manufacturer for each implant – yes, it’s work, and yes, it’s work worth doing.
Finally, even the original invoice is for a device with a markup that is, well, huge. One analyst estimates gross margins are in the 80% range…driving profit margins that are the envy of any payer or health system.
The net? Kudos to IL for recognizing and addressing this issue. Now it will be up to payers to enforce the regulation, by demanding the actual invoice, not one developed in the basement. They may also want the provider’s notarized statement that the invoice is the real, actual, honest-to-goodness true price net of rebates, discounts, etc.


Jul
6

Coventry’s $278 million miscue

Coventry Health will be taking a $278 million charge against earnings to cover the company’s fine plus interest and legal costs resulting from last week’s Louisiana appellate courte ruling in a workers comp PPO network case.
On a per-share basis, the bill is $1.18 pre-tax.
the charge will be partially offset by improved earnings from other sectors, including Medicare Advantage Private-Fee-for-Service. According to Zacks, the “2010 EPS outlook was also revised to $1.57−$1.72 in view of the impact of the charge, down from the prior range of $2.35−$2.50 per share. Excluding the charge, Coventry anticipates the EPS outlook to increase by 40 cents per share to range between $2.75 and $2.90.”
Since moving back into the executive suite over a year ago, CEO and Chairman Allen Wise has done an excellent job turning the company around – refocusing the company on its core businesses, shedding underperforming and inefficient operations and profit centers, even revamping the way the company negotiates provider contracts to focus on Medicaid, Medicare, group, and individual health businesses.
The quarter-billion dollar charge is undoubtedly the subject of much discussion at the company’s, executive committee meetings as it will suck cash out of the coffers that would have been used to acquire more regional health plans and help Coventry prepare for the post-reform health insurance world. It is also notable as it comes from a division, workers comp, which heretofore had been a cash machine, generating significantly more profits than its rather modest top line would predict.
For now, Coventry appears to be weathering the storm, recently announcing the acquisition of a couple of regional health plans and predicting continued improvements in operating earnings.
Whether this continues may depend in some part on the outcome of the company’s appeal of the LA case.


Jul
2

Yesterday’s Louisiana appellate court ruling against Coventry’s First Health work comp network is a major blow to comp insurers, employers, and networks in Louisiana, with potential impact in other states as well.
The ruling is here.
The court’s finding supported a lower court’s ruling affirming a state statute requiring PPOs to provide injured workers with PPO identity cards or give notice to providers 30 days before taking discounts. While Coventry will appeal to the state Supreme Court, the appellate court ruled against almost all of Coventry’s arguments, making this an uphill battle for the nation’s biggest work comp managed care firm. I’d also note that the decision itself takes Coventry’s legal team to task for failings to accurately cite evidence in its written appeal, stating the “failure to provide record citations suggests that many of these assignments were interposed only for purposes of delay and confusion.”
Ouch. (no pun intended)
While the finding may be bad enough, the size of the penalty is stunning – Coventry will have to pay $262 million – $2000 for each of the “131,024 instances in the past 10 years when it discounted providers’ charges below the state workers’ compensation fee schedule.” (WorkCompCentral)
Some workers comp networks decided early on to avoid doing business at all in LA; MedRisk (HSA client) left the state after the initial ruling against Coventry along with several other PPO and specialty networks.
Implications
For Coventry, it doesn’t look good. While I’ve taken the company to task in the past for what I perceive to be missteps, and some would argue that they should have pulled out long ago, it’s hard to fault Coventry for believing they could conduct business in LA as they do in most other states, by contracting with providers to deliver discounted care to workers comp claimants. The additional notice requirements in Louisiana are unique to that state; in retrospect all networks should have picked up on this nuance, but in retrospect we all would have sold our stocks two months ago…
It doesn’t look good for employers in Louisiana either. As MedRisk’s General Counsel, Darrell Demoss noted in the WorkCompCentral piece, WCRI data suggests comp medical costs are significantly higher in Louisiana than in other states. Now that the ruling has been upheld, expect insurers and managed care organizations to avoid the state completely in fear that they too could be nailed by class-action suit.
On a national basis, this ruling will likely cause many network vendors and insurers to stop and very carefully review each state’s laws and regulations pertaining to networks, with compliance staffs tasked with doubly ensuring their contracts comply with the letter and spirit of each jurisdiction’s rules and regs. That’s not a bad thing, as it’s a heck of a lot cheaper to pay attorneys and compliance staff than a $262 million penalty.
What does this mean for you?
Sorry, but bad news on a Friday – and a holiday Friday at that.
Except if you’re a comp provider in LA.

Thanks to WorkCompCentral for the heads up.


Jul
1

Injury rates – (very) early indications of increases

Anecdotal information indicates the comp injury rate is heading up just a bit. In email conversations with Jim Greenwood, CEO of Concentra, Inc., the nation’s largest occ/urgent care clinic company, Jim sounded encouraged by the upward trend in the company’s growth, particularly in an increase in patient visits.
Concentra is seeing its strongest growth “in the Great Lakes (Chicago, Michigan,
Indiana, Ohio and Western PA), followed closely by the Mid Atlantic / New Jersey / Philadelphia.
Texas is also doing well, but “activity levels in the southeast, far southwest and west coast [are] best described as moderate on a relative basis.”
According to Greenwood, the growth in patient visits appears to be due to two primary factos: increased hiring in the transportation sector and greater market share for Concentra’s clinics.
Department of Labor employment data doesn’t necessarily correlate with Concentra’s results. For example, Texas employment was up by 43,600 in May, and California saw 28,300 net new jobs that month; TX correlates with Concentra results but California doesn’t. And, a spokesman for DoL noted: ” the worst hit states remain the housing bubble states and manufacturing states around the Great Lakes…”.
What does this mean for you?
If you’re in the work comp services business, a little good news. Employment is clearly nowhere near where anyone would like it to be, but it is improving, if ever so slowly.